Open Access
Open access

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

Alfredo Tartarone 1
Vittoria Lapadula 1
Concetta Di Micco 2
Gemma Rossi 3
Carlotta Ottanelli 3
Andrea Marini 3
Roberta Giorgione 3
Katia Ferrari 4
Martina Catalano 3
Luca Voltolini 5
Enrico Mini 6
Giandomenico Roviello 6
Publication typeJournal Article
Publication date2021-05-21
scimago Q2
wos Q2
SJR1.075
CiteScore6.9
Impact factor3.3
ISSN2234943X
Cancer Research
Oncology
Abstract

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.

Found 
Found 

Top-30

Journals

1
Molecular and Cellular Biochemistry
1 publication, 9.09%
Current Medical Research and Opinion
1 publication, 9.09%
Diagnostic Pathology
1 publication, 9.09%
Cancer genetics
1 publication, 9.09%
Journal of Chromatography A
1 publication, 9.09%
Mathematical Biosciences and Engineering
1 publication, 9.09%
Journal of Translational Medicine
1 publication, 9.09%
Extracellular Vesicles and Circulating Nucleic Acids
1 publication, 9.09%
Frontiers in Oncology
1 publication, 9.09%
1

Publishers

1
2
3
Springer Nature
3 publications, 27.27%
Elsevier
2 publications, 18.18%
Taylor & Francis
1 publication, 9.09%
American Institute of Mathematical Sciences (AIMS)
1 publication, 9.09%
OAE Publishing Inc.
1 publication, 9.09%
Frontiers Media S.A.
1 publication, 9.09%
1
2
3
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
11
Share
Cite this
GOST |
Cite this
GOST Copy
Tartarone A. et al. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer // Frontiers in Oncology. 2021. Vol. 11.
GOST all authors (up to 50) Copy
Tartarone A., Lapadula V., Di Micco C., Rossi G., Ottanelli C., Marini A., Giorgione R., Ferrari K., Catalano M., Voltolini L., Mini E., Roviello G. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer // Frontiers in Oncology. 2021. Vol. 11.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.3389/fonc.2021.632256
UR - https://doi.org/10.3389/fonc.2021.632256
TI - Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
T2 - Frontiers in Oncology
AU - Tartarone, Alfredo
AU - Lapadula, Vittoria
AU - Di Micco, Concetta
AU - Rossi, Gemma
AU - Ottanelli, Carlotta
AU - Marini, Andrea
AU - Giorgione, Roberta
AU - Ferrari, Katia
AU - Catalano, Martina
AU - Voltolini, Luca
AU - Mini, Enrico
AU - Roviello, Giandomenico
PY - 2021
DA - 2021/05/21
PB - Frontiers Media S.A.
VL - 11
PMID - 34094913
SN - 2234-943X
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Tartarone,
author = {Alfredo Tartarone and Vittoria Lapadula and Concetta Di Micco and Gemma Rossi and Carlotta Ottanelli and Andrea Marini and Roberta Giorgione and Katia Ferrari and Martina Catalano and Luca Voltolini and Enrico Mini and Giandomenico Roviello},
title = {Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer},
journal = {Frontiers in Oncology},
year = {2021},
volume = {11},
publisher = {Frontiers Media S.A.},
month = {may},
url = {https://doi.org/10.3389/fonc.2021.632256},
doi = {10.3389/fonc.2021.632256}
}